参考文献

［1］STAMATOPOULOS K，AGATHANGELIDIS A，ROSENQUIST R，et al.Antigen receptor stereotypy in chronic lymphocytic leukemia［J］.Leukemia，2017，31（2）：282-291.

［2］YOUNG R M，WU T，SCHMITZ R，et al.Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens［J］.Proc Natl Acad Sci U S A，2015，112（44）：13447-1354.

［3］HADZIDIMITRIOU A，AGATHANGELIDIS A，DARZENTAS N，et al.Is there a role for antigen selection in mantle cell lymphoma？Immunogenetic support from a series of 807 cases［J］.Blood，2011，118（11）：3088-3095.

［4］CATERA R，SILVERMAN G J，HATZI K，et al.Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation［J］.Mol Med，2008，14（11-12）：665-674.

［5］CHU C C，CATERA R，ZHANG L，et al.Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain ⅡA：implications for patient outcome and cell of origin［J］.Blood，2010，115（19）：3907-3915.

［6］JOHNSON A R，KOHLI P B，KATEWA A，et al.Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations［J］.ACS Chem Biol，2016，11（10）：2897-2907.

［7］BRANDHUBER B，GOMEZ E，SMITH S，et al.LOXO-305，A Next Generation Reversible BTK Inhibitor，for Overcoming Acquired Resistance to Irreversible BTK Inhibitors［J］.Clinical Lymphoma，Myeloma and Leukemia，2018，18（Supplement 1）：S216.

［8］REIFF S D，MANTEL R，SMITH L L，et al.The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation［J］.Cancer Discov，2018，8（10）：1300-1315.

［9］WOYACH J A.Ibrutinib and Aspergillus：a Btk-targeted risk［J］.Blood，2018，132（18）：1869-1870.

［10］HUANG X，QIU L，JIN J，et al.Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma：a randomized，open-label phase 3 study［J］.Cancer Med，2018，7（4）：1043-1055.

［11］XU W，YANG S，ZHOU K，et al.Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia：34-month follow-up results［C］.The Hague：EHA Library，2021.

［12］XU W，SONG Y，WANG T，et al.Updated Results from the PhaseⅡ Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia［J］.Blood，2020，136（Supplement 1）：26-27.

［13］PAOLO GHIA A P，MALGORZATA WACH.Acalabrutinib vs Rituximab Plus Idelalisib（IdR）or Bendamustine（BR）by Investigator Choice in Relapsed/Refractory（RR）Chronic Lymphocytic Leukemia：Phase 3 ASCEND Study［C］.Lugano：15th International Conference on Malignant Lymphoma Palazzo dei Congressi，Switzerland，2019.

［14］BARR P M，ROBAK T，OWEN C，et al.Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia：extended phase 3 results from RESONATE-2［J］.Haematologica，2018，103（9）：1502-1510.

［15］TAM C S，ROBAK T，GHIA P，et al.Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia（CLL）or Small Lymphocytic Lymphoma（SLL）with Del（17p）：Initial Results from Arm C of the Sequoia（BGB-3111-304）Trial［J］.Blood，2019，134（Supplement_1）：499.

［16］SHARMAN J P，EGYED M，JURCZAK W，et al.Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia（ELEVATE TN）：a randomised，controlled，phase 3 trial［J］.Lancet，2020，395（10232）：1278-1291.

［17］HILLMEN P，EICHHORST B，BROWN J R，et al.First interim analysis of alpine study：results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma［C］.The Hague：EHA Library，2021.

［18］BYRD J C，HILLMEN P，GHIA P，et al.CLL-115：First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia［J］.Clinical lymphoma，myeloma ＆ leukemia，2021，21（supplement 1）：S318.

［19］CHANG B Y，FRANCESCO M，DE ROOIJ M F，et al.Egress of CD19（+）CD5（+）cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients［J］.Blood，2013，122（14）：2412-2424.

［20］RULE S，JURCZAK W，JERKEMAN M，et al.Ibrutinib versus temsirolimus：3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3，international，randomized，open-label RAY study［J］.Leukemia，2018，32（8）：1799-1803.

［21］SONG Y，ZHOU K，ZOU D，et al.Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib，a Selective Inhibitor of Bruton's Tyrosine Kinase［J］.Clin Cancer Res，2020，26（16）：4216-4224.

［22］WANG M，RULE S，ZINZANI P L，et al.Acalabrutinib in relapsed or refractory mantle cell lymphoma（ACE-LY-004）：a single-arm，multicentre，phase 2 trial［J］.Lancet，2018，391（10121）：659-667.

［23］SONG Y，SONG Y，LIU L，et al.Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma：A Multicenter，Open-Label，Phase Ⅱ Study［J］.Blood，2019，134（Supplement_1）：755.

［24］GARCÍA-SANZ R，MONTOTO S，TORREQUEBRADA A，et al.Waldenström macroglobulinaemia：presenting features and outcome in a series with 217 cases［J］.Br J Haematol，2001，115（3）：575-582.

［25］TREON S P，TRIPSAS C K，MEID K，et al.Ibrutinib in previously treated Waldenström's macroglobulinemia［J］.N Engl J Med，2015，372（15）：1430-1440.

［26］TROTMAN J，OPAT S，MARLTON P，et al.PF481 updated safety and efficacy data in a phase 1/2 trial of patients with waldenström macroglobulinaemia（WM）treated with the bruton tyrosine kinase（BTK）inhibitor zanubrutinib（BGB-3111）［J］.HemaSphere，2019，3（S1）：192-193.

［27］TAM C S，OPAT S，D'SA S.ASPEN：Results of a Phase 3 Randomized Trial of Zanubrutinib versus Ibrutinib for Patients with Waldenström Macroglobulinemia（WM）［C］.Chicago：the 2020 Annual Meeting of the American Society of Clinical Oncology（ASCO），2020.

［28］GOLDSTEIN J S，SWITCHENKO J M，BEHERA M，et al.Insurance status impacts overall survival in Burkitt lymphoma［J］.Leuk Lymphoma，2019，60（13）：3225-3234.

［29］KANSARA R.Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma［J］.Curr Treat Options Oncol，2018，19（11）：52.

［30］THIEBLEMONT C，BERNARD S，MEIGNAN M，et al.Optimizing initial therapy in DLBCL［J］.Best Pract Res Clin Haematol，2018，31（3）：199-208.

［31］SAGIV-BARFI I，KOHRT H E，CZERWINSKI D K，et al.Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib，an inhibitor of both BTK and ITK［J］.Proc Natl Acad Sci U S A，2015，112（9）：E966-E972.

［32］WILSON W H，YOUNG R M，SCHMITZ R，et al.Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma［J］.Nat Med，2015，21（8）：922-926.

［33］TAM C S，SIMPSON D，OPAT S，et al.Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma［J］.Blood，2017，130（Supplement 1）：152.

［34］DASMAHAPATRA G，PATEL H，DENT P，et al.The Bruton tyrosine kinase（BTK）inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma（DLBCL）and mantle cell lymphoma（MCL）cells sensitive or resistant to bortezomib［J］.Br J Haematol，2013，161（1）：43-56.

［35］SCHMITZ R，WRIGHT G W，HUANG D W，et al.Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma［J］.N Engl J Med，2018，378（15）：1396-1407.

［36］WRIGHT G W，HUANG D W，PHELAN J D，et al.A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications［J］.Cancer Cell，2020，37（4）：551-568.e14.

［37］LIONAKIS M S，DUNLEAVY K，ROSCHEWSKI M，et al.Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma［J］.Cancer Cell，2017，31（6）：833-843.e5.

［38］DUCHARME O，BEYLOT-BARRY M，PHAM-LEDARD A，et al.Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type［J］.J Invest Dermatol，2019，139（11）：2334-2342.e8.

［39］FRICK M，BETTSTETTER M，BERTZ S，et al.Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL［J］.Leuk Lymphoma，2018，59（5）：1260-1263.

［40］VISCO C，TANASI I，QUAGLIA F M，et al.Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice［J］.Cancers（Basel），2020，12（10）：2913.

［41］J T L，K B P.Ibrutinib in primary central nervous system diffuse large B-cell lymphoma［J］.CNS Oncol，2020，9（1）：Cns51.

［42］纪婷婷，陈秋妮，陶善东，等.BTK抑制剂在B细胞肿瘤治疗中的研究进展［J］.中国实验血液学杂志，2020，28（01）：333-338.

［43］NOY A，DE VOS S，THIEBLEMONT C，et al.Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma：A Multicenter，Open-Label，Phase 2 Study［J］.Blood，2016，128（22）：1213.

［44］BARTLETT N L，COSTELLO B A，LAPLANT B R，et al.Singleagent ibrutinib in relapsed or refractory follicular lymphoma：a phase 2 consortium trial［J］.Blood，2018，131（2）：182-190.

［45］GOPAL A K，SCHUSTER S J，FOWLER N H，et al.Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma：Results From the Open-Label，Multicenter，Phase ⅡDAWN Study［J］.J Clin Oncol，2018，36（23）：2405-2412.

［46］FOWLER N H，DAVIS R E，RAWAL S，et al.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma：an open-label，phase 2 trial［J］.Lancet Oncol，2014，15（12）：1311-1318.

［47］TAM C S，SIMPSON D，OPAT S，et al.Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma［J］.Blood，2017，130（Supplement 1）：152.

［48］COUTRE S E，BYRD J C，HILLMEN P，et al.Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies［J］.Blood Adv，2019，3（12）：1799-1807.

［49］BARR P M，MUNIR T，BROWN J R，et al.Final analysis from RESONATE：Six-year follow-up in patients（pts）with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma（CLL/SLL）on ibrutinib［J］.Journal of Clinical Oncology，2019，37（15_suppl）：7510.

［50］S T C，S O，J Z.PS1159 Pooled analysis of safety data from monotherapy studies of the bruton tyrosine kinase（BTK）inhibitor，Zanubrutinib（BGB-3111），in B-cell malignancies［J］.Hema Sphere，2019，3（S1）：S526.

［51］SYED Y Y.Zanubrutinib：First Approval［J］.Drugs，2020，80（1）：91-97.

［52］BYRD J C，BROWN J R，O'BRIEN S，et al.Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia［J］.N Engl J Med，2014，371（3）：213-223.

［53］BURGER J A，TEDESCHI A，BARR P M，et al.Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia［J］.N Engl J Med，2015，373（25）：2425-2437.

［54］O'BRIEN S，HILLMEN P，COUTRE S，et al.Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma［J］.Clin Lymphoma Myeloma Leuk，2018，18（10）：648-657.e15.

［55］BYRD J C，WIERDA W G，SCHUH A，et al.Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia：updated phase 2 results［J］.Blood，2020，135（15）：1204-1213.

［56］FLINN I，SHADMAN M，FREEMAN B B，et al.Trial in progress：a phase Ⅱ，multicenter，single-arm study of zanubrutinib（BGB-3111）in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib［J］.Journal of Clinical Oncology，2020，38（15_suppl）：TPS8066-TPS.

［57］WIERDA W G，BYRD J C，ABRAMSON J S，et al.Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma，Version 4.2020，NCCN Clinical Practice Guidelines in Oncology［J］.J Natl Compr Canc Netw，2020，18（2）：185-217.

［58］WOYACH J A，FLINN I W，STEPHENS D M，et al.A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies［J］.Blood，2018，132（Supplement 1）：3136.

［59］CHERNG H-J J，JAIN N.First-Line Therapy for Chronic Lymphocytic Leukemia：Bruton Tyrosine Kinase or BCL2 or Both？［J］.Hematology/Oncology Clinics of North America，2021，35（4）：725-738.